AB Science: FINANCIAL CALENDAR

Fri Dec 21, 2012 2:02pm EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20121221:nBw215821a

PARIS--(Business Wire)--
Regulatory News: 

AB Science (Paris:AB): 

2013 Publications

Press releases are distributed after the closing of the stock market. 

April 29th : 2013 First Quarter Revenue and 2012 Full Year Revenue & Results 

August 29th : 2013 Half-Year Sales & Results 

October 15th : 2013 Third Quarter Revenue 

About AB Science

Founded in 2001, AB Science is a pharmaceutical company specializing in the
research, development and commercialization of protein kinase inhibitors (PKIs),
a new class of targeted molecules whose action is to modify signaling pathways
within cells. Through these PKIs, the Company targets diseases with high unmet
medical needs (cancer, inflammatory diseases, and central nervous system
diseases), in both human and veterinary medicines. AB Science has developed a
proprietary portfolio of molecules and the Company`s lead compound, masitinib,
has already been registered for veterinary medicine in Europe and in the USA,
and is pursuing 8 on-going phase 3 studies in human medicine in GIST, metastatic
melanoma expressing JM mutation of c-Kit, multiple myeloma, mastocytosis, severe
persistent asthma, rheumatoid arthritis, and progressive multiple sclerosis. The
company is headquartered in Paris, France, and listed on Euronext Paris (ticker:
AB). 

Further information is available on AB Science`s website: www.ab-science.com

This document contains prospective information. No guarantee can be given as for
the realization of these forecasts, which are subject to those risks described
in documents deposited by the Company to the Authority of the financial markets,
including trends of the economic conjuncture, the financial markets and the
markets on which AB Science is present.

AB Science - Financial Communication & Press Relations
investors@ab-science.com



Copyright Business Wire 2012
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.